CD137L was also expressed on tumor cells and suggested that the interaction of CD137 and CD137L promoted tumor cell proliferation, survival, migration, and tumorigenesis and might be a promising therapeutic target for MF/SS [28,29,30,31]. The gene discussed is TNFRSF9; the disease is neoplasm.